Ken Griffin Axogen, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Axogen, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,100 shares of AXGN stock, worth $532,127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,100
Previous 40,700
1.47%
Holding current value
$532,127
Previous $328,000
11.59%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding AXGN
# of Institutions
138Shares Held
36.1MCall Options Held
79.1KPut Options Held
500-
Arrow Mark Colorado Holdings LLC Denver, CO5.12MShares$67.9 Million0.49% of portfolio
-
First Light Asset Management, LLC Edina, MN3.34MShares$44.4 Million2.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.31MShares$43.9 Million2.42% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$43.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.52MShares$33.4 Million0.0% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $561M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...